Int J Med Rev 2024 December;11(4): 797-803

10.30491/IJMR.2024.487660.1298

INTERNATIONAL JOURNAL OF MEDICAL REVIEWS

Mini Review

Assessing the Pandemic Potential and Implications for Global Health Security

Sirvan Abbasbeigi [1*]

[1] Cellular and Molecular Biology/Biochemistry Department, Islamic Azad University (IAU), Science and Research Branch, Tehran, Iran

*** Corresponding Author:** Sirvan Abbasbeigi, Cellular and Molecular Biology/Biochemistry Department, Islamic Azad University (IAU), Science and Research Branch, Tehran, Iran. E-mail: nemesis.student@gmail.com

Received November 7, 2024; **Accepted** December 24, 2024; **Online Published** December 30, 2024

Abstract

The resurgence of the Mpox virus in various regions has raised significant concerns regarding its potential to evolve into a global pandemic, mainly due to the rising rates of human-to-human transmission. This review aims to delve into the intricate aspects of Mpox by analyzing recent epidemiological data, transmission dynamics, clinical features, and public health responses. Our primary objective is to evaluate the pandemic potential of Mpox by comparing the current situation to established pandemic criteria. This evaluation will consider factors that may facilitate or impede the virus's spread among populations. To bolster our findings, we have gathered data from reputable sources, including peer-reviewed studies, reports from health organizations, and case analyses. While interventions like isolation and ring vaccination have effectively managed localized outbreaks, several challenges remain. These challenges primarily stem from limitations in resource allocation, vaccine availability, and the complexities of international coordination during health emergencies. Furthermore, this review will identify gaps in our understanding and management of Mpox, which are essential for shaping future pandemic preparedness strategies. We will also present actionable recommendations to enhance our response to Mpox and similar infectious diseases. This review aspires to comprehensively understand Mpox's pandemic potential by thoroughly exploring these elements. Our findings are intended to serve as a valuable resource for public health professionals, policymakers, and researchers dedicated to improving global health security in the face of emerging infectious threats.

Keywords: Mpox Virus, Pandemic Potential, Transmission Dynamics, Public Health Response, Vaccine Availability, Global Health Security

Introduction

The Mpox virus, classified within the Orthopoxvirus genus, has attracted considerable scholarly attention in recent years due to its zoonotic characteristics and potential to escalate into a significant public health threat.[1] Initially identified in laboratory monkeys in 1958, the virus was subsequently confirmed in human populations in 1970 in the Democratic Republic of Congo, marking a critical juncture in its epidemiological history.[2] Mpox shares a genetic lineage with other prominent poxviruses, including smallpox and cowpox, raising concerns regarding its capacity to induce severe infections and the broader implications for public health.[3] Historically confined to Central and West Africa, Mpox has exhibited concerning trends in its geographic spread, particularly since 2022.[4] The emergence of cases in non-endemic countries, where the virus had not previously been reported, underscores the need for enhanced surveillance and international response efforts to contain and prevent further outbreaks.[5] The global movement of people and animals and various environmental factors significantly facilitate the virus's dissemination.[6] To mitigate the stigma associated with its original nomenclature, the virus has been rebranded from “monkeypox” to “Mpox”.[7] This renaming initiative is part of a broader campaign to raise public awareness and foster a more accurate understanding of the virus, emphasizing the necessity of viewing it through a public health framework rather than one characterized by fear or stigma related to its origins. The discontinuation of routine smallpox vaccination programs, coupled with the increasing interconnectedness of the global community, underscores the imperative of comprehending smallpox's pandemic potential.[8] Public health officials recognize that the immunological landscape changes significantly as younger generations exhibit diminishing immunity to related viruses.[9] As research

on Mpox advances, monitoring its transmission dynamics and virulence and the efficacy of public health interventions designed to mitigate its spread will be crucial. Ultimately, proactive strategies and informed public discourse will be vital in addressing the challenges posed by Mpox and safeguarding global health.



Figure 1. This document presents an overview of the Mpox pandemic potential assessment, highlighting critical areas of analysis, including epidemiological considerations, transmission dynamics, public health responses, challenges in management, and recommendations for optimizing response strategies.

Materials and Methods

This review utilizes a structured and systematic approach to gather and analyze data from reputable databases. These include established resources such as PubMed, the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and Scopus. We focus on relevant studies published until October 2023, ensuring that the information we compile is current and applicable. To direct our search, we employed specific terms vital for understanding the implications of the Mpox virus. These terms included "Mpox virus", "transmission dynamics", "epidemiology", and "pandemic potential". Each of these areas is essential for assessing the spread of the virus and its impact on public health. Our inclusion criteria were meticulously crafted to prioritize recent publications that offer substantial data regarding Mpox transmission, its clinical manifestations, and the responses implemented by public health organizations. We deliberately chose to exclude studies that did not provide original data or primarily focused on unrelated Orthopoxviruses, as they would not offer valuable insights into the specific

context of Mpox. The present analysis synthesizes various critical components, including epidemiological data, detailed clinical case studies, and effective public health strategies across different regions. By integrating these diverse elements, we aim to provide a comprehensive overview of the current status of the Mpox virus and its potential trajectory in the future. This review highlights the existing knowledge and identifies gaps that require further investigation to enhance our understanding and response strategies regarding Mpox.

Our Understanding

Current Epidemiological Trends

The epidemiology of Mpox has evolved significantly in recent years. Traditionally, this virus was endemic to specific regions of Central and West Africa, and global awareness was limited until recent outbreaks began to emerge beyond these areas.[10] The epidemics of 2022-2023 represented a notable shift in the behavior of the virus, with case numbers surging in countries that had previously reported few or no cases, including North America, Europe, and parts of Asia.[11] These outbreaks have been marked by a rapid increase in incidence and occasional fatalities, particularly among immunocompromised individuals.[12] Mpox remains a persistent health threat in endemic regions, with data indicating ongoing transmission, especially among populations with regular contact with animal reservoirs.[13] This transition from a localized zoonotic infection to widespread human transmission underscores the urgent need for global vigilance and enhanced surveillance to prevent further outbreaks.[14]



Figure 2. The management of the Mpox outbreak presents several critical challenges, including the dynamics of transmission, the availability of vaccines, the formulation of public health responses, and the insights gained from the COVID-19 pandemic. This framework is intended to facilitate more effective outbreak control strategies.

Transmission Dynamics and Mechanisms

Mpox transmission occurs through various pathways, starting with zoonotic spillovers and progressing to more prevalent human-to-human transmission.[15] Animal reservoirs, particularly rodents and primates, serve as primary sources of zoonotic infection, with transmission to humans occurring through close contact with or handling infected animals.[16] Deforestation, the bushmeat trade, and encroachment on wildlife habitats increase human exposure, elevating the likelihood of spillover events.[17] Once Mpox is present within human populations, it primarily spreads through skin-to-skin contact and

respiratory droplets, with fomite transmission (the transfer of viruses from contaminated surfaces) playing a lesser role.[18] Recent evidence indicates that respiratory secretions may contribute to transmission during close, prolonged interactions, although airborne spread remains a topic of ongoing debate.[19] Understanding these dynamics is essential for formulating effective containment and prevention strategies, especially in high-risk communities where skin contact is expected.[20]

Clinical Features and Diagnostics

Mpox infection unfolds in distinct stages, starting with an incubation period. This is followed by symptoms such as fever, muscle aches, and the development of characteristic rashes.[21] The severity of the disease varies; some individuals may exhibit mild symptoms, while others may experience significant complications, particularly those with compromised immune systems.[22] Diagnosing Mpox can prove challenging due to symptom similarities with other rash-inducing illnesses, such as chickenpox and measles.[23] Accurate diagnosis depends on laboratory confirmation through PCR and serological testing. However, limited access to these diagnostic resources in underserved regions hampers effective outbreak management.[24] Furthermore, asymptomatic and mild cases present a hidden risk, as individuals may unknowingly transmit the infection to others, complicating efforts to track and contain outbreaks.[25]

Public Health Responses and Control Measures

Public health responses to Mpox have primarily focused on containment measures such as isolation, contact tracing, and vaccination strategies.[26] A notable approach has been ring vaccination, which involves administering vaccines to individuals who have been in contact with confirmed cases, thereby limiting further transmission.[27] However, logistical challenges persist, particularly in regions with inadequate healthcare infrastructure or vaccine supplies.[28] In areas affected by Mpox, public health agencies recommend quarantine protocols for both confirmed and suspected cases to mitigate the spread of the virus.[29] Vaccine hesitancy, fueled by misinformation and a lack of public awareness, poses an additional challenge that undermines the effectiveness of vaccination campaigns.[30] Furthermore, effective public health strategies require cross-border coordination and resource sharing, which, despite ongoing efforts, remain inconsistent and are often complicated by disparities in healthcare resources.[31]

Vaccine Availability and Efficacy

Existing vaccines, including ACAM2000 and MVA-BN, initially developed for smallpox, demonstrate potential in preventing Mpox.[32] However, their effectiveness varies, and some adverse effects have been reported, particularly among individuals with underlying health conditions.[33] Distribution poses a significant challenge, as manufacturing and logistical limitations have restricted global vaccine availability, especially in low-resource settings.[34] The gap in vaccine access between high-income and low-income countries emphasizes the necessity for equitable distribution strategies to ensure that vulnerable populations receive sufficient protection.[35] Ongoing research into Mpox-specific vaccines explores innovative platforms and technologies to develop safer and more effective immunizations.[36] These initiatives are crucial to preventing Mpox from becoming a persistent global health burden.

Lessons from the COVID-19 Pandemic

The COVID-19 pandemic highlighted several critical areas for improving outbreak response.[37] It emphasized the need for solid surveillance systems, prompt international cooperation, and combating misinformation.[38] Effective surveillance systems that provide early warnings and enable real-time data collection are essential for timely intervention, especially regarding zoonotic diseases like Mpox.[39] As outlined in agreements like the International Health Regulations, enhancing global collaboration is vital for facilitating resource sharing, expediting vaccine distribution, and supporting regions with limited resources.[40] Furthermore, fostering public trust through clear and transparent communication is crucial, as misinformation can undermine public health efforts and contribute to vaccine hesitancy.[41] The insights gained from COVID-19 provide a valuable framework for strengthening preparedness and enhancing responses to potential future pandemics.[42]

Discussion

The evaluation of the pandemic potential of Mpox necessitates a comprehensive analysis of criteria established by prominent global health organizations,



Figure 3. An examination of the factors influencing the pandemic potential of Mpox—specifically, global connectivity, the waning of immunity, intervention strategies, and the robustness of public health infrastructure—is paramount for the assessment and mitigation of future pandemic risks.

such as the World Health Organization (WHO).[43] Critical factors for consideration include transmissibility, severity, and patterns of international spread.[44] Mpox exhibits specific characteristics consistent with recognized pandemic threats; notably, it demonstrates sustained human-to-human transmission and has been observed disseminating beyond its endemic regions.[45] However, a pivotal aspect that may constrain its potential to precipitate a widespread pandemic is its relatively low transmissibility compared to highly contagious viruses, such as SARS-CoV-2.[46] This diminished transmission rate can be a natural impediment to large-scale outbreaks; nonetheless, it does not negate the imperative for continual vigilance and preparedness.[47] Several mitigating factors contribute to the effective control of Mpox's spread. Public health infrastructure enhancement facilitates more robust surveillance and response strategies.[48] Furthermore, the availability of effective vaccines significantly bolsters the capacity to manage potential outbreaks.[49] Implementing established intervention strategies, including contact tracing and quarantine measures, also plays an essential role in mitigating the virus's potential impact.[50] It is imperative to consider the broader contextual factors influencing the dynamics of Mpox. Global connectivity and international travel can accelerate the virus's transmission, enabling it to reach regions that may not have previously faced outbreaks.[10,51] Additionally, concerns regarding waning immunity within populations due to the cessation of smallpox vaccination programs warrant attention,[52] as this decline in immunity may render certain demographic groups more susceptible to infection and complicate control efforts.[53] Although the current limitations on transmissibility and the concerted efforts of public health interventions offer some degree of reassurance, it remains essential to reinforce these measures consistently.[54] This includes ongoing public health campaigns aimed at increasing awareness, ensuring adequate vaccination coverage, and maintaining rigorous surveillance systems for the prompt detection and response to emerging cases.[55] While Mpox presents

specific characteristics indicative of a potential pandemic threat, its impact is tempered by protective and vulnerability factors.[56] Maintaining a state of preparedness and adapting strategies to emerging data will be crucial for mitigating any risks associated with this virus.[57]

Conclusion

In summary, Mpox represents a significant public health threat due to its zoonotic origins, rising human-to-human transmission, and its reach beyond endemic regions. While current data do not indicate an imminent pandemic, the evolving epidemiological trends necessitate sustained vigilance and proactive containment measures. Key findings suggest that, although existing vaccines and containment strategies provide a degree of control, there are notable gaps in global health preparedness, disparities in vaccine access, and the risk of undetected cases. To effectively mitigate the impact of Mpox, it is crucial to continue investing in surveillance, vaccine research, and international collaboration. The global health community must prioritize these efforts to avert Mpox from escalating into a more significant public health crisis.

Conflict of Interest

The authors declare no conflicts of interest.

Acknowledgement

To enhance the clarity and readability of our manuscript, we employed Grammarly's AI and the GPT-4 Omni models to provide suggestions for alternative sentence structures. These AI tools were supervised by human researchers who integrated their expertise to refine the suggestions, ensuring both precision and academic integrity.

References

1. Duarte PM, Adesola RO, Priyadarsini S, Singh R, Shaheen MN, Ogundijo OA, et al. Unveiling the Global Surge of Mpox (Monkeypox): A comprehensive review of current evidence. Microbe. 2024:100141. doi:10.1016/j.microb.2024.100141
2. Hungwe FT, Laycock KM, Ntereke TD, Mabaka R, Paganotti GM. A historical perspective on arboviruses of public health interest in Southern Africa. Pathog Glob Health. 2024;118(2):131-59. doi:10.1080/20477724.2023.2290375
3. Bhardwaj P, Sarkar S, Mishra R. Mpox and related poxviruses: A literature review of evolution, pathophysiology, and clinical manifestations. Asian Pac J Trop Biomed. 2024;14(8):319-30. doi:10.4103/apjtb.apjtb_193_24
4. Gao L, Shi Q, Dong X, Wang M, Liu Z, Li Z. Mpox, Caused by the MPXV of the Clade IIb lineage, goes global. Trop Med Infect Dis. 2023;8(2):76. doi:10.3390/tropicalmed8020076
5. Hewson R. Understanding Viral Haemorrhagic Fevers: Virus Diversity, Vector Ecology, and Public Health Strategies. Pathogens. 2024;13(10):909. doi:10.3390/pathogens13100909
6. Kaiwan O, Sethi Y, Khehra N, Padda I, Chopra H, Chandran D, et al. Emerging and re-emerging viral diseases, predisposing risk factors, and implications of international travel: A call for action for increasing vigilance and imposing restrictions under the current threats of recently emerging multiple Omicron subvariants. Int J Surg. 2023;109(3):589-91. doi:10.1097/JS9.0000000000000176
7. Umar TP, Jain N, Sayad R, Tandarto K, Jain S, Reinis A. Overcoming Stigma: The Human Side of Monkeypox Virus. Poxviruses. 2024:383-97. doi:10.1007/978-3-031-57165-7_25
8. Ogunleye SC, Akinsulie OC, Aborode AT, Olorunshola MM, Gbore D, Oladoye M, et al. The re-emergence and transmission of Monkeypox virus in Nigeria: the role of one health. Front Public Health. 2024;11:1334238. doi:10.3389/fpubh.2023.1334238
9. Chatterjee S, Bhattacharya M, Nag S, Dhama K, Chakraborty C. A detailed overview of SARS-CoV-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. Viruses. 2023;15(1):167. doi:10.3390/v15010167
10. Mohapatra RK, Singh PK, Branda F, Mishra S, Kutikuppala LS, Suvvari TK, et al. Transmission dynamics, complications and mitigation strategies of the current mpox outbreak: A comprehensive review with bibliometric study. Rev Med Virol. 2024;34(3):e2541. doi:10.1002/rmv.2541
11. Du J, Lang H-m, Ma Y, Chen A-w, Qin Y-y, Zhang X-p, et al. Global trends in COVID-19 incidence and case fatality rates (2019–2023): a retrospective analysis. Front Public Health. 2024;12:1355097. doi:10.3389/fpubh.2024.1355097
12. Mitja O, Ogoina D, Titanji BK, Galvan C, Muyembe J-J, Marks M, et al. Monkeypox. Lancet. 2023;401(10370):60-74. doi:10.1016/S0140-6736(22)02075-X
13. hauhan RP, Fogel R, Limson J. Overview of diagnostic methods, disease prevalence and transmission of MPOX (formerly monkeypox) in humans and animal reservoirs. Microorganisms. 2023;11(5):1186. doi:10.3390/microorganisms11051186
14. Marty AM, Beÿ CK, Koenig KL. 2024 Mpox outbreak: A rapidly evolving public health emergency of international concern: Introduction of an Updated Mpox Identify-Isolate-Inform (3I) Tool. One Health. 2024;19:100927. doi:10.1093/ofid/ofac310
15. Gao S, Zeng Z, Xin Q, Yang M, Feng X, Liu X, et al. Global transboundary transmission path and risk of Mpox revealed with Least Cost Path model. International J Infect Dis. 2024;146:107101. doi:10.1016/j.ijid.2024.107101
16. Esposito MM, Turku S, Lehrfield L, Shoman A. The impact of human activities on zoonotic infection transmissions. Animals. 2023;13(10):1646. doi:10.3390/ani13101646
17. Manes C, Carthy RR, Hull V. A coupled human and natural systems framework to characterize emerging infectious diseases—the case of fibropapillomatosis in marine turtles. Animals. 2023;13(9):1441. doi:10.3390/ani13091441
18. Cices A, Prasad S, Akselrad M, Sells N, Woods K, Silverberg NB, et al. Mpox Update: Clinical Presentation, Vaccination Guidance, and Management. Cutis. 2023;111(4):197-202. doi:10.12788/cutis.0745
19. Ijaz MK, Sattar SA, Nims RW, Boone SA, McKinney J, Gerba CP. Environmental dissemination of respiratory viruses: dynamic interdependencies of respiratory droplets, aerosols, aerial particulates, environmental surfaces, and contribution of viral re-aerosolization. PeerJ. 2023;11:e16420. doi:10.7717/peerj.16420
20. Singh P, Sridhar SB, Shareef J, Talath S, Mohapatra P, Khatib MN, et al. The resurgence of monkeypox: Epidemiology, clinical features, and public health implications in the post-smallpox eradication era. New Microbes and New Infections. 2024:101487. doi:10.1016/j.nmni.2024.101487
21. Ganesan A, Arunagiri T, Mani S, Kumaran VR, Sk G, Elumalai S, et al. Mpox treatment evolution: past milestones, present advances, and future directions. Naunyn Schmiedebergs Arch Pharmacol. 2024:1-24. doi:10.1007/s00210-024-03385-0
22. Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, et al. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother. 2023;168:115734. doi:10.1016/j.biopha.2023.

115734
23. Asif S, Zhao M, Li Y, Tang F, Ur Rehman Khan S, Zhu Y. AI-Based Approaches for the Diagnosis of Mpox: Challenges and Future Prospects. Arch Comput Methods Eng. 2024:1-33. doi:10.1007/s11831-024-10091-w
24. Tawfick MM, Badawy MSE, Taleb MH, Menofy NGE. Tuberculosis Diagnosis and Detection of Drug Resistance: A Comprehensive Updated Review. J Pure Appl Microbiol. 2023;17(4). doi:10.22207/JPAM.17.4.56
25. Mehraeen E, Akhtaran FK, Faridrohani MR, Afzalian A, Mojdeganlou H, Ghanbari Z, et al. Estimating the Size of the Hidden Population of COVID-19. Infect Disord Drug Targets. 2024;24(2):37-45. doi:10.2174/0118715265255039231018113634
26. Norberg AN, Norberg PRBM, Manhres FC, Souza DGd, Queiroz MMdC, Neto CHG, et al. Public Health Strategies Against Social Stigma in the Mpox Outbreak: A Systematic Review. J Adv Med Med Res. 2024;36(2):33-47. doi:10.9734/jammr/2024/v36i25365
27. Kandeel M, Morsy MA, Abd El-Lateef HM, Marzok M, El-Beltagi HS, Al Khodair KM, et al. Efficacy of the modified vaccinia Ankara virus vaccine and the replication-competent vaccine ACAM2000 in monkeypox prevention. Int Immunopharmacol. 2023;119:110206. doi:10.1016/j.intimp.2023.110206
28. Haldane V, Ariyarajah A, Berry I, Loutet M, Salamanca-Buentello F, Upshur RE. Global inequity creates local insufficiency: A qualitative study of COVID-19 vaccine implementation challenges in low-and-middle-income countries. PloS One. 2023;18(2):e0281358. doi:10.1371/journal.pone.0281358
29. Zhang W, Qi X, Han B, Fu L, Wang B, Wu K, et al. Efforts made, challenges faced, and recommendations provided by stakeholders involved in mpox prevention and control in China: a qualitative study. Public Health. 2024;236:115-24. doi:10.1016/j.puhe.2024.07.014
30. Okoro YO, Ayo-Farai O, Maduka CP, Okongwu CC, Sodamade OT. A review of health misinformation on digital platforms: challenges and countermeasures. Int J Appl Res Soc Sci. 2024;6(1):23-36. doi:10.51594/ijarss.v6i1.689
31. Towett G, Snead RS, Grigoryan K, Marczika J. Geographical and practical challenges in the implementation of digital health passports for cross-border COVID-19 pandemic management: a narrative review and framework for solutions. Global Health. 2023;19(1):98. doi:10.1186/s12992-023-00998-7
32. Grabenstein JD, Hacker A. Vaccines against Mpox: MVA-BN and LC16m8. Expert Rev Vaccines. 2024;23(1):796-811. doi:10.1080/14760584.2024.2397006
33. Titanji BK, Hazra A, Zucker J. Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review. JAMA. 2024. doi:10.1001/jama.2024.21091
34. Verma A, Khatib MN, Sharma GD, Singh MP, Bushi G, Ballal S, et al. Mpox 2024: New variant, new challenges, and the looming pandemic. Clin Infect Pract. 2024:100394. doi:10.1016/j.clinpr.2024.100394
35. Williams JT, T O'Leary S. Multilevel approaches to immunization equity. Curr Opin Immunol. 2024;91:102496. doi:10.1016/j.coi.2024.102496
36. Saadh MJ, Ghadimkhani T, Soltani N, Abbassioun A, Pecho RDC, Kazem TJ, et al. Progress and prospects on vaccine development against monkeypox infection. Microb Pathog. 2023;180:106156. doi:10.1016/j.micpath.2023.106156
37. Abbasbeigi S. COVID-19 treatments| A glance at the most recent reported drugs, which may close to the operational phase. International J Med Rev. 2021;8(1):20-4. doi:10.30491/ijmr.2020.246764.1140
38. Abbasbeigi S. CRISPR-Cas9: The Association between SARS-CoV-2 and Neurodegenerative Disorders (NDDs) Occurrence. International J Med Rev. 2023;10(4):625-36. doi:10.30491/ijmr.2023.412298.1265
39. Aggarwal S, Agarwal P, Nigam K, Vijay N, Yadav P, Gupta N. Mapping the Landscape of Health Research Priorities for Effective Pandemic Preparedness in Human Mpox Virus Disease. Pathogens. 2023;12(11):1352. doi:10.3390/pathogens12111352
40. Al Meslamani AZ. Advancing towards a worldwide healthcare system in the post-COVID-19 era: benefits and barriers to international collaboration in healthcare. Taylor & Francis; 2023. pp. 679-81.
41. Pennisi F, Genovese C, Gianfredi V. Lessons from the COVID-19 Pandemic: Promoting Vaccination and Public Health Resilience, a Narrative Review. Vaccines. 2024;12(8):891. doi:10.3390/vaccines12080891
42. Khorram-Manesh A, Goniewicz K, Burkle Jr FM. Unleashing the global potential of public health: a framework for future pandemic response. J Infect Public Health. 2024;17(1):82-95. doi:10.1016/j.jiph.2023.10.038
43. Okoli GN, Van Caeseele P, Askin N, Abou-Setta AM. A global systematic evidence review with meta-analysis of the epidemiological characteristics of the 2022 Mpox outbreaks. Infection. 2024;52(3):901-21. doi:10.1007/s15010-023-02133-5
44. Núñez-Cortés R, Calatayud J, López-Gil JF, Koyanagi A, Casana J, López-Bueno R. Risk profile and mode of transmission of Mpox: a rapid review and individual patient data meta-analysis of case studies. Rev Med Virol. 2023;33(2):e2410. doi:10.1002/rmv.2410
45. Branda F, Romano C, Ciccozzi M, Giovanetti M, Scarpa F, Ciccozzi A, et al. Mpox: An Overview of Pathogenesis, Diagnosis, and Public Health Implications. J Clin Med. 2024;13(8):2234. doi:10.3390/jcm13082234
46. Bragazzi NL, Woldegerima WA, Wu J, Converti M, Szarpak L, Crapanzano A, et al. Epidemiological and Clinical Characteristics of Mpox in Cisgender and Transgender Women and Non-Binary Individuals Assigned to the Female Sex at Birth: A Comprehensive, Critical Global Perspective. Viruses. 2024;16(3):325. doi:10.3390/v16030325
47. Mohsenpour A, Bozorgmehr K, Rohleder S, Stratil J, Costa D. SARS-Cov-2 prevalence, transmission, health-related outcomes and control strategies in homeless shelters: systematic review and meta-analysis. EClinicalMedicine. 2021;38. doi:10.1016/j.eclinm.2021.101032
48. Khan I, Mahalakshmi S, Dixit T, Shinkre R, Ravindran S, Bandyopadhyay S. Differential diagnosis, prevention measures, and therapeutic interventions for enhanced monkeypox (mpox) care. Cureus. 2024;16(5):e60724. doi:10.7759/cureus.60724
49. Protopapas K, Dimopoulou D, Kalesis N, Akinosoglou K, Moschopoulos CD. Mpox and Lessons Learned in the Light of the Recent Outbreak: A Narrative Review. Viruses. 2024;16(10):1620. doi:10.3390/v16101620
50. Ahmed SK, Dabou EA, Ibrahim FM, Mohammed MG, Chandran D, Basit J, et al. Challenges and Counteracting Strategies Including Optimum Health Service Practices for Frontline Nurses During the Mpox Outbreak and Futuristic Vision. SAGE Open Nurs. 2024;10:23779608241256209. doi:10.1177/23779608241256209
51. Paparini S, Whelan I, Mwendera C, Hayes R, Maatouk I, Lewis R, et al. Prevention of sexual transmission of mpox: a systematic review and qualitative evidence synthesis of approaches. Infect Dis. 2024;56(8):589-605. doi:10.1080/23744235.2024.2364801
52. Zebardast A, Latifi T, Shafiei-Jandaghi N-Z, Gholami Barzoki M, Shatizadeh Malekshahi S. Plausible reasons for the resurgence of Mpox (formerly Monkeypox): an overview. Trop Dis Travel Med Vaccines. 2023;9(1):23. doi:10.1186/s40794-023-00209-6
53. Acharya A, Kumar N, Singh K, Byrareddy SN. Mpox in MSM: Tackling Stigma, Minimizing Risk Factors, Exploring Pathogenesis, and Treatment Approaches. Biomed J. 2024:100746. doi:10.1016/j.bj.2024.100746
54. Otmar CD, Merolla AJ. Social determinants of message exposure and health anxiety among young sexual minority men in the United States during the 2022 mpox outbreak. Health Commun. 2024:1-2. doi:10.1080/10410236.2024.2397272
55. Halwani MA. Endemic Cross-transmission of Mpox within Health-care Settings: A Comprehensive Review. Hail J Health Sci. 2024;6(1):9-18. doi:10.4103/hjhs.hjhs_8_24
56. Duda R, Betoulet JM, Besombes C, Mbrenga F, Borzykh Y, Nakouné E, et al. A time of decline: An eco-anthropological and ethnohistorical investigation of mpox in the Central African Republic. PLOS Glob Public Health. 2024;4(3):e0002937. doi:10.1371/journal.pgph.0002937
57. El Dine FB, Gebreal A, Samhouri D, Estifanos H, Kourampi I, Abdelrhem H, et al. Ethical considerations during Mpox Outbreak: a scoping review. BMC Med Ethics. 2024;25(1):79. doi:10.1186/s12910-024-01078-0